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A B S T R A C T
The impact of L-arginine (LA), a precursor for synthesis of nitric oxide (NO), and N-w -nitro-L-arginine methyl ester
(L-NAME, LN), a non-selective inhibitor of the enzyme producing nitric oxide (nitric oxide synthase; NOS) chronic toxic-
ity induced lesions on Ascites – Pulmonary hypertension syndrome (PHS) development was investigated in 140 one-day-
-old male broiler chickens (ROSS) during the first 5 weeks of life. Every second day the animals were treated intra-
peritoneally (ip) with L-NAME (10 mg/kg of body weight; BW), L-arginine (100 mg/kg BW), L-arginine and L-NAME in
combination (100 mg/kg BW and 10 mg/kg BW, respectively), and with physiological saline (0.90% w/v of NaCl; 0.5
mL/kg BW). Seven birds from each group were euthanized every week. The histopathological examination of the heart,
the liver, the lungs, the blood vessels and the lymphoid organs, was performed. Also the organ index values were deter-
mined. At the end of the experiment the pre-ascitic condition or ascites – PHS was confirmed in five dead animals in the
L-NAME-treated group. In the same group the edema was the most prominent histopathological change confirmed in the
heart and in the lungs of the sacrificed chickens. In L-arginine-treated group the congestion and the haemorrhages were
the striking changes in the same organs with the highest degree in the last two weeks of trial. While the focal disruption
of myocardiofibriole and hepatocytes were predominant lesions in L-NAME-treated chickens (5thand 4th weeks, respec-
tively), in L-NAME/L-arginine-treated group only the mild focal myocardial degeneration was seen. According to the
most of the results of present investigation, it was concluded that the consecutive treatment with L-NAME provoked
ascites – PHS, while L-arginine has protective effect in this animal model of disease.
Key words: broiler, Ascites – Pulmonary hypertension syndrome (PHS), nitric oxide, L-NAME, L-arginine, histopa-
thology, organ index
Introduction
Ascites – pulmonary hypertension syndrome (PHS) is
a metabolic condition in fast-growing-broilers character-
ized by an elevated pulmonary vascular resistance (PVR)
and pulmonary hypertension (PH), accompained by hy-
poxemia, and resulting in right ventricular failure (RVF),
central venous congestion, and hepatic cirrhosis and
ascites1–9. As in humans, severe PH leads to severe limi-
tations of functional status and poor survival10.
Affecting the young broilers (mostly in age of 4–5
weeks, sometimes even earlier in the age of 11–15 days of
life11–12), and generally causing the mortality from 5–8%
in populations worldwide, and even as great as 20 to 30%
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in heavier broiler flocks13–16, ascites – PHS may cause the
significant economic losses in the commercial broiler in-
dustry throughout the world, especially if broilers are
reared with exposure to cold or at high altitude12,17–21.
Over the period 1991 to 2009, in broiler chicken produc-
tion in the Republic of Croatia, the average ascites-PHS
mortality rate was 13% of the overall reported infectious
and non-infectious disease mortality22.
Considering these data, one can conclude that the
broiler treatment with the pulmonary vasodilatators would
reduce the incidence of this cardiovascular disease in
broilers. Hypoxia-induced vasoconstriction and subse-
quent PH was prevented when a dietary L-arginine was
used as the main source of a potent endogenous endothe-
lial vasodilatator – nitric oxide in broilers chronically ex-
posed to the cold23. The opposite was confirmed in PHS-
-chickens where the treatment with the L-NAME, a
non-selective nitric oxide synthase (NOS) inhibitor, was
used24. Nitric oxide is a well known physiological and
pathophysiological mediator, especially as a potent pul-
monary vasodilator in mammals and birds24–37. Also the
pathogenesis of PHS in broiler chicken is very similar to
human idiopathic pulmonary arterial hypertension
(IPAH)38. In cardiovascular system nitric oxide is pro-
duced in blood vessel endothelium, myocardium and
endocardium39, and its impaired endothelial production
has been implicated in the pathophysiology of PH in
humans40. Since the L-NAME was confirmed as a cause
of the ascites – PHS24,29,32,36,37,41–43, and the salutary ef-
fect of L-arginine was proved through the measures in
prevention and therapy of this disease40,42,43, we investi-
gated here the effects of the chronic use of these sub-
stances in broiler chickens on ascites – PHS development.
Materials and Methods
Chickens and husbandry
One hundred and fourty 1-day-old broiler male ROSS
chicks were included in this study and kept in metal wire
cages placed in an acclimatised object (temperature of
35oC, relative humidity of 64%). They were allowed 11
days for acclimatization. Food and water were provided
ad libitum. The animals were fed commercial diet for
broilers (»starter« and »finisher«; »Poljoprerada«, Hrvat-
ski Leskovac, Croatia). On the 15th day of life the chick-
ens were vaccinated against Newcastle disease (Pesti-
kal®, LaSota SPF, Pliva, Croatia), using the occulonasal
(on) method.
Experimental design and sampling procedures
Chemical substances used in this experiment were
L-arginine (ICN Biomedicals, Cleveland, USA), L-NAME
(N-w-nitro-L-arginine methyl ester HCl; ICN Biomedi-
cals, Cleveland, USA) and saline.
Birds were divided into four groups of 35 chickens: 1)
control – C; physiological saline – 0.90% w/v of Na Cl (0,5
mL/kg BW); 2) L-arginine – LA; 100 mg/kg BW; 3) L-
-NAME – LN; 10 mg/kg BW; 4) L-NAME and L-arginine,
in combination – L-NAME/Larginine; 10 mg/kg BW and
100 mg/kg BW, respectively. Intraperitoneal (ip) treat-
ment was started on 11th day of life. The animals were
treated with the same doses every second day for the
next 5 weeks. Seven chicks from each group were killed
(a cervical dislocation under chloroform anaesthesia) at
the end of every week and necropsied.
Histopathology
For histopathological analysis the tissue samples (the
heart, the lungs, the liver, the bursa of Fabricius, the thy-
mus, then spleen, the blood vessels /aorta and pulmonary
artery), were fixed in neutral 10%-formalin solution, em-
bedded in paraffin and 4 mm thick sections were prepared
(MICROM HM 325, Zeiss, Austria). After deparaffiniza-
tion, the sections were stained with haematoxylin and
eosin (HE). The slices were examined under the light mi-
croscope (LEICA DMLB, Germany) and images were
captured with digital camera PIXERA Pro 150ES.
Organ index value
Organ index values (the liver-, the heart-, the bursa of
Fabricius-, the spleen-, and the thymus – index values)
were counted according to the equation:
Organ mass / Body mass ´ 1000
Statistical analysis
The data were statistically analyzed in accordance
with the standard statistical programme (DOS MICRO-
STAT statistics package Rel. 4.1.06.)44. The results ob-
tained by the organ mass-index values data, were statis-
tically analyzed by means of one-way analysis of variance
(ANOVA), followed by the Kruskall-Wallis’ and the Wil-
coxon’s test. The Mann-Whitney U-test was used for be-
tween two independent groups’ comparisons. P values
less than 0.05 were considered statistically significant.
Results
Gross lesions
Post-mortem examination did not reveal notable dif-
ferences between the control and the treated groups of
chickens sacrificed at the end of each week. However, five
animals from the L-NAME-treated group died after the
fifth trial week under the typical signs of ascites – PHS or
in pre-ascitic (hypoxic) condition. The gross lesions in-
cluded: cyanosis of the head and the neck skin and mu-
cous membrane, increased moistness of the thoracic-ab-
dominal cavity or ascites, hydropericardium, dilatation
or hypertrophy of the right cardiac ventricle, of the ve-
nous sinus and of the vena cava in three of five chickens.
Edema and pulmonary hyperemia, an enlarged and
hyperemic liver with sporadically pronounced necrosis
were noted in all 3 experimental groups of chickens. In
the chickens with the so-called preascitic state, cyanosis
and thoracic muscular anemia were visible, increased
moistness of the thoracic-abdominal cavity, a moderate
pulmonary oedema and hepatomegalia.




While the histopathological examination revealed ex-
tremely slight, mostly degenerative changes in the con-
trol chicken group (Figure 9), prominent edema and a
high degree of parenchymatous degeneration followed by
the disruption and necrosis of myofibriole (Figure 1) and
myofibrillar disruption and disorganization (Figure 2),
as well as focal fibroplasia (Figure 3), were recorded in
the L-NAME group at the end of the experiment (5th
week). In the trial group treated with L-arginine, the
most severe microscopic changes – hyperemia and mostly
focal hemorrhages, were seen toward the end of the ex-
periment (from 3rd to 5th trial weeks) (Figure 4). Con-
trarily, the changes in the animals simultaneously trea-
ted with L-arginine and L-NAME were recognized as
mild myocardial degeneration and edema.
Lungs
In the lungs, the most striking findings in both L-
-NAME- and L-arginine-treated groups were perivas-
cular edema and congestion, followed by hemorrhages,
especially prominent in the L-arginine-treated chickens
at the end of the experiment (Figure 5). Cartilaginous
nodules were also recorded from the 3rd to 5th trial week
in the L-NAME-treated group (Figure 6), along with the
collapsed atria and parabronchial dilatation, and with
the hypertrophy of the muscular arteries’ wall (Figure
7). Focal mononuclear hyperplasia, the fibrinoid fluid
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Fig. 1. Diffuse parenchymatous degeneration followed by a pro-
minent interfibrilar edema and focal disruption of myofibriole
(arrows) (L-NAME-tretated group of chickens, 5th wk) (scale
bar=50 mm).
Fig. 2. Disruption and disorganization of the myocardial fibres
(arrows) (L-NAME-treated group of chickens, 5th wk) (scale
bar=50 mm).
Fig. 3. Focal fibroplasia (arrows) in myocardium (L-NAME-
-treated group of chickens; 5th wk) (scale bar=50 mm).
Fig. 4. Hyperemia and mostly focal (perivascular) hemorrhages
(arrows) in myocardium (L-arginine-treated group of chickens,
4th wk) (scale bar=50 mm).
Fig. 5. Lung congestion, perivascular edema and fribrinoid fluid
(arrows), followed by hemorrhage (L-arginine-treated group of
chickens, 5th wk) (scale bar=50 mm).
and the parabronchial smooth muscle hypertrophy were
seen in the 5th week of the experiment in L-NAME-
-treated group. Mild to prominent congestion associated
with hemorrhages, as well as with the occurrence of car-
tilaginous nodules in the parenchyma were also seen in
the L-arginine-treated group of chickens, these changes
being of a higher degree toward the end of the experi-
ment. Just slight to mild edema and congestion were re-
corded during the experimental period in the L-NAME/
L-arginine-treated group (Figure 10).
Liver
The most prominent histopathological changes were
seen in the liver in the L-NAME- and in the L-arginine
chicken groups. As in the heart and in the lungs, mild to
prominent edema (L-NAME-treated group, 5rd wk; Fig-
ure 11) and congestion in the L-NAME-treated chickens
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Fig. 6. Cartilaginous nodule in lungs (arrow) (L-NAME-treated
group of chickens, 4th wk) (scale bar=50 mm).
Fig. 7. Hypertrophy of the smooth muscle layer in the small ar-
teries in lungs (arrows) (L-NAME-treated group of chickens, 4th
wk) (scale bar=50 mm).
Fig. 8. Perivascular disruption of hepatocytes (arrows) and coag-
ulation necrosis (arrow head) (L-NAME-treated group of chick-
ens, 4th wk) (scale bar=50 mm).
Fig. 9. Heart (control group of chickens, 2nd wk) (scale bar=50 mm).
Fig. 10. Lungs no apparent lesions (L-NAME/L-arginine group
of chickens, 2nd wk) (scale bar=50 mm).
Fig. 11. Prominent interstitial edema in liver (L-NAME group of
chickens, 5th wk) (scale bar=10 mm).
along with the hyperemia and hemorrhages of various
degree in the L-arginine group, were the most prominent
liver changes found in these two trial groups. Also, pe-
rivascular disruption of hepatocytes and coagulation ne-
crosis were found in the L-NAME-treated chicken group
(4th wk, Figure 8). In the L-NAME/L-arginine-treated
chickens mostly mild edema and parenchymatous degen-
eration were established.
Organ index values
The differences in the mean organ index values as
well as the mean body values, the organ index values,
standard deviation and the standard error, and the in-
terquartile range in the control and study chicken groups
are shown in Tables 1–9.
Discussion and Conclusions
During the whole experimental period there were no
notable gross pathomorphological changes in the control
and treated groups of chickens, sacrificed at the end of
each week. However, at the end of the experiment, five
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TABLE 1
STATISTICAL SIGNIFICANCE VALUES OF MEAN LIVER INDEX
VALUES IN THE CONTROL AND TREATED GROUPS
Groups
Weeks of trial
1 2 3 4 5
C 35.15 29.63 27.45 26.29 24.95
LN 34.79** 29.13 30.36* 24.8# 25.12#
LA 34.09$ 28.65 25.96 34.35* 37.08*
LN/LA 29.98* 27.68 24.32** 27.59 34.32*
**, *, #, $– p<0.05; *LN/LA vs. C, LN vs. C, LA vs. C, $LN/LA vs. LA;
**LN/LA vs. LN; #LN vs. LA; groups: LN/LA – LN- and L-argini-
ne; LA – L-arginine; LN – L-NAME; C – control
TABLE 2
STATISTICAL SIGNIFICANCE OF MEAN HEART INDEX VALUES
IN THE CONTROL AND TREATED GROUPS OF CHICKENS
Groups
Weeks of the experiment
1 2 3 4 5
C 6.27 6.70 5.76 5.57 4.67
LN 6.62** 6.32 6.39 5.93 5.21**
LA 6.92 6.97 5.94 5.79 5.65
LN/LA 5.26$ 6.88 6.42* 4.74* 6.18$
**, *, $ – p<0.05; *LN/LA vs. C; $LN/LA vs. LA; **LN/LA vs. LN;
LN/LA – L-NAME- and L-arginine-treated group; C – control group;
LA – L-arginine-treated group; LN – L-NAME-treated group
TABLE 3
STATISTICAL SIGNIFICANCE OF MEAN SPLEEN INDEX VALUES
IN THE CONTROL AND TREATED GROUPS OF CHICKENS
Groups
Weeks of trial
1 2 3 4 5
C 0.96 0.95 1.77 2.00 1.20
LN 1.07 1.31 1.24 1.73 1.76
LA 1.06 0.81 0.71* 4.64 2.04
LN/LA 0.86 1.05 1.57 2.20 1.76
*p<0.05; *LA vs. C; groups: LA – L-arginine, C – control; LN-
-L-NAME; LN/LA-LN-L-NAME and LA – L-arginine
TABLE 4
STATISTICAL SIGNIFICANCE OF MEAN THYMUS INDEX




1 2 3 4 5
C 3.75 4.64 3.79 4.9 4.55
LN 3.54 4.24$ 3.61 3.75 5.16#
LA 3.02 5.21 3.68 3.18 1.83*
LN/LA 3.47 3.60 4.63 3.59 4.32
$, *, # – p<0.05; $LN/LA vs. LA; *LA vs. C; #LN vs. LA; groups:
LN/LA – L-NAME- and L-arginine; LN – L-NAME; LA – L-ar-
ginine; C – control
TABLE 5
MEAN BODY WEIGHT AND ORGAN INDEX VALUES, STANDARD
DEVIATION (SD), STANDARD ERROR (SE), AND INTERQUARTILE
RANGE (M) IN THE CONTROL AND TREATED GROUPS OF
CHICKENS (1ST WK OF TRIAL)
Groups BW (gm) LI SI HI TI BFI
C n 7 7 7 7 7 7
x 391.21 35.15 0.96 6.27 3.75 3.46
SD 23.06 5.50 0.33 0.62 1.63 0.82
SE 8.72 2.08 0.12 0.24 0.62 0.31
M 390.20 35.38 0.98 6.33 3.33 3.33
LA n 7 7 7 7 7 7
x 393.69 34.09 1.06 6.92 3.02 4.00
SD 55.39 2.70 0.49 0.42 0.47 0.80
SE 20.94 1.02 0.18 0.16 0.18 0.30
M 379.30 33.82 1.05 6.95 2.94 4.26
LN n 7 7 7 7 7 7
x 409.59 34.79 1.07 6.62 3.54 3.35
SD 57.02 3.53 1.05 0.53 1.53 0.66
SE 21.55 1.33 0.40 0.20 0.58 0.25
M 411.30 35.08 0.75 6.73 3.69 3.33
LN/LA n 7 7 7 7 7 7
x 387.00 29.98 0.86 5.26 3.47 3.38
SD 58.78 2.28 0.44 1.96 1.11 1.02
SE 22.22 0.86 0.17 0.74 0.42 0.38
M 362.60 29.47 0.84 5.71 3.14 3.03
Groups: LN/LA – L-NAME- and L-arginine, LN – L-NAME, LA
– L-arginine, C – control; Body weight – BW; Liver index – LI,
Spleen index – SI, Heart index – HI, Thymus index – TI, Bursa
of Fabricius index – BFI; gram – gm; n – number of animals, x –
mean values
chickens were found dead with the signs of pre-ascitic
states and of ascites-PHS in the group daily treated with
L-NAME over five weeks. The gross lesions seen in the
fifth trial week obviously confirmed that the consecutive
treatment of the chickens with L-NAME (in a dose of 10
mg/kg BW, ip) has been provoked the pre-ascitic condi-
tion or the ascites – PHS29. The histopathological find-
ings were typical for pre-ascitic condition as well as for
the chickens with ascites – PHS12,45. The same findings
were confimed in broiler chickens 1, 2 and 4 hours after
the start of the intravenous infusion of L-NAME as well
as in broilers fed with the diet supplemented with 100
ppm of L-NAME up to 4 week32. Perivascular edema of a
high degree as well as focal disruption and necrosis of
myofibriole and myofibrillar disruption and disorganiza-
tion (Figures 1 and 2, respectively) were observed in
hearts of chickens died in the fifth study week. In hy-
poxic heart muscle the death of individual cardiac myo-
cytes followed by the lengthening, thinning, and finally
disrupting of the cardiac myofibres has been a common
phenomenon (dilated cardiomyopathy)46,47. So, it seemed
to be possible that except of a high degree of interfibrilar
edema, this could be also the cause of myofibrilar disrup-
tion followed by the disorganization and attempted fago-
cytosis of the damaged heart muscular tissue (Figure 2).
The change of focal myofibriole disruption (Figure 1)
could be the consequence of the myocardiotropism of
L-NAME, i.e. its cardiotoxic effect29.
The important fact is that the structure of the bird’s
heart favors the development of ascites-PHS. The thin-
-wall right ventricle rapidly responds to the increased ac-
tion (e.g. in hypoxia) with both dilatation and hypertrophy
of the atrioventricular valve itself (that results in valvu-
lar insufficiency) and with the development of ascites48.
The focal fibroplasia (Figure 3) was recorded in LN-
-treated chickens in 5th wk of trial. According to some
investigatiors in case of endocardiosis (the histopatho-
logical change recorded in our trial as the mild one in the
heart of L-NAME-treated, ascitic bird), the myocardial
fibrosis has to be the one of the most common accompa-
nying manifestation49.
In the fifth study week, numerous, although not ex-
tensive, predominantly capillary hemorrhages were an-
other change in the chickens treated with L-NAME. This
might be a consequence of increased coronary vascular
permeability induced by direct and indirect action of
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TABLE 6
MEAN BODY WEIGHT AND ORGAN INDEX VALUES, STANDARD
DEVIATION (SD), STANDARD ERROR (SE), AND INTERQUARTILE
RANGE (M) IN THE CONTROL AND TREATED GROUPS OF
CHICKENS (2nd WK OF TRIAL)
Groups BW (gm) LI SI HI TI BFI
C n 7 7 7 7 7 7
x 682.71 29.63 0.95 6.70 4.64 3.75
SD 44.32 6.41 0.55 0.47 1.34 0.51
SE 16.75 2.42 0.21 0.18 0.51 0.19
M 678.00 27.34 1.04 6.72 4.48 4.06
LA n 7 7 7 7 7 7
x 649.14 28.65 0.81 6.97 5.21 3.96
SD 71.29 2.75 0.52 0.92 1.56 0.64
SE 26.95 1.04 0.20 0.35 0.59 0.24
M 633.00 28.91 0.95 7.11 4.74 3.96
LN n 7 7 7 7 7 7
x 631.29 29.13 1.31 6.32 4.24 3.40
SD 52.38 5.65 0.36 0.48 0.75 0.49
SE 19.80 2.14 0.14 0.18 0.28 0.19
M 632.00 28.16 1.16 6.26 4.47 3.48
LN/LA n 7 7 7 7 7 7
x 684.00 27.68 1.05 6.88 3.60 3.63
SD 56.87 2.47 0.28 0.94 0.84 0.65
SE 21.50 0.94 0.10 0.35 0.32 0.24
M 672.00 27.33 0.97 7.06 3.27 3.78
Groups: LN/LA – L-NAME- and L-arginine, LN – L-NAME, LA
– L-arginine, C – control; Body weight – BW; Liver index – LI,
Spleen index – SI, Heart index – HI, Thymus index – TI, Bursa
of Fabricius index – BFI; gram – gm; n – number of animals, x –
mean values
TABLE 7
MEAN BODY WEIGHT AND ORGAN INDEX VALUES, STANDARD
DEVIATION (SD), STANDARD ERROR (SE), AND INTERQUARTILE
RANGE (M) IN THE CONTROL AND TREATED GROUPS OF
CHICKENS (3rd WK OF TRIAL)
Groups BW (gm) LI SI HI TI BFI
C n 7 7 7 7 7 7
x 1083.14 24.75 1.77 5.76 3.79 2.80
SD 145.12 1.78 0.53 0.68 0.47 0.60
SE 54.85 0.67 0.20 0.26 0.18 0.23
M 1070.00 25.05 1.64 5.78 3.65 2.73
LA n 7 7 7 7 7 7
x 1129.86 25.96 0.71 5.94 3.68 8.12
SD 65.00 2.69 0.63 0.62 1.19 13.33
SE 24.57 1.02 0.24 0.24 0.45 5.04
M 1153.00 26.75 0.86 5.62 3.19 3.92
LN n 7 7 7 7 7 7
x 1014.29 30.36 1.24 6.39 3.61 2.83
SD 237.52 5.60 0.72 0.97 1.64 1.09
SE 89.78 2.12 0.27 0.37 0.62 0.41
M 1067.00 30.31 0.96 6.48 2.99 2.84
LN/LA n 7 7 7 7 7 7
x 1107.57 24.32 1.57 6.42 4.63 2.26
SD 107.36 1.68 0.97 0.32 1.36 0.33
SE 40.58 0.64 0.37 0.12 0.51 0.13
M 1120.00 24.73 1.59 6.45 4.52 2.22
Groups: LN/LA – L-NAME- and L-arginine, LN – L-NAME, LA
– L-arginine, C – control; Body weight – BW; Liver index – LI,
Spleen index – SI, Heart index – HI, Thymus index – TI, Bursa
of Fabricius index – BFI; gram – gm; n – number of animals, x –
mean values
L-NAME. However, the highest extent of congestion and
hemorrhage, the prevalent changes in the myocardia of
L-arginine-treated chickens, was observed over the last
two weeks of the trial (Figure 4). These hemorrhages
have been presented as scattered intramyocardial, more
rarely subepicardial and subendocardial. A role of NO in
preventing of platelet accumulation and aggregation in
blood vessels wall50,51 might also contribute to the ap-
pearance of the hemorrhages in the hearts of chickens
treated with L-arginine over a long period of time.
In the chicken group treated simultaneously with
L-arginine and L-NAME, only myocardial degeneration
prevailed. It may be presumed that the simultaneous ad-
ministration of L-arginine with the L-NAME did miti-
gate, if not prevent, L-NAME’s action as a potent vaso-
constrictor, at least during the first three trial weeks. In
fact, while L-NAME has been acting as a non-selective
inhibitor of NOS, supplemental L-arginine has been shown
to prevent reduced expression of endothelial nitric oxide
synthase (eNOS) in broiler chickens40. Since the L-ar-
ginine concentrations in birds are correlated with dietary
intake (because L-arginine is an essential amino-acid in
birds’ organism)31,52, the supplemental L-arginine is es-
sential for the reducing of pulmonary arterial pressure
(PAP) and the incidence of pulmonary hypertension syn-
drome (PHS) in broilers42. Obviously, the constitutive
NO synthesis contributes modestly to maintaining the
basal tone of the pulmonary vasculature53. Also the peri-
vascular disruption of hepatocytes and the coagulation
necrosis (Figure 8), were found in chickens treated by
L-NAME and were considered a result of chronic L-
-NAME-toxic effect29. Sinusoidal congestion, intravas-
cular coagulation, and coagulation necrosis around the
central veins were prominent in the L-NAME group of
rats but not in the N-w-nitro-D-arginine (D-NAME) group
of rats (both groups were previously treated by dimethyl-
nitrosamine)54. Obviously the coagulation necroses, con-
firmed in livers of animals treated with L-NAME repre-
sents the consequences of its vasoconstrictory and/or
toxic effect in liver tissue. As in the present experiment,
the findings of the interstitial edema, was described by
numerous authors as regular histopathological finding in
hypoxic or ascitic chickens55–58.
Development of cartilaginous and/or osseous nodules
in the lungs (Figure 6) as a regular concomitant patho-
logical change in ascitic chickens has been well des-
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TABLE 8
MEAN BODY WEIGHT AND ORGAN INDEX VALUES, STANDARD
DEVIATION (SD), STANDARD ERROR (SE), AND INTERQUARTILE
RANGE (M) IN THE CONTROL AND TREATED GROUPS OF
CHICKENS (4th WK OF TRIAL)
Groups BW (gm) LI SI HI TI BFI
C n 7 7 7 7 7
x 1556.43 26.29 2.00 5.57 4.90 2.86
SD 168.03 3.12 0.75 0.48 1.57 0.63
SE 63.51 1.18 0.28 0.18 0.59 0.24
M 1586.00 25.65 2.21 5.49 4.87 2.83
LA n 7 7 7 7 7 7
x 1366.29 34.35 4.64 5.79 3.18 2.34
SD 264.76 9.05 8.04 1.55 1.53 0.79
SE 100.07 3.42 3.04 0.59 0.58 0.30
M 1442.00 29.30 1.95 5.47 3.08 2.21
LN n 7 7 7 7 7 7
x 1568.43 24.80 1.73 5.93 3.75 2.89
SD 142.21 2.96 0.91 0.61 1.12 0.63
SE 53.75 1.12 0.34 0.23 0.42 0.24
M 1520.00 23.29 1.94 6.02 3.46 2.59
LN/LA n 7 7 7 7 7 7
x 1591.57 27.59 2.20 4.74 3.59 2.50
SD 114.01 3.31 2.71 0.45 0.70 0.60
SE 43.09 1.25 1.02 0.17 0.26 0.23
M 1565.00 26.47 1.78 4.56 3.69 2.51
Groups: LN/LA – L-NAME- and L-arginine, LN – L-NAME, LA
– L-arginine, C – control; Body weight – BW; Liver index – LI,
Spleen index – SI, Heart index – HI, Thymus index – TI, Bursa
of Fabricius index – BFI; gram – gm; n – number of animals, x –
mean values
TABLE 9
MEAN BODY WEIGHT AND ORGAN INDEX VALUES, STANDARD
DEVIATION (SD), STANDARD ERROR (SE), AND INTERQUARTILE
RANGE (M) IN THE CONTROL AND TREATED GROUPS OF
CHICKENS (5th WK OF TRIAL)
Groups BW (gm) LI SI HI TI BFI
C n 6 6 6 6 6 6
x 2261.50 24.95 1.20 4.67 4.55 2.62
SD 281.97 4.05 0.65 0.49 0.67 0.76
SE 115.11 1.65 0.27 0.20 0.27 0.31
M 2197.50 24.91 1.25 4.73 4.32 2.46
LA n 5 5 5 5 5 5
x 1648.20 37.08 2.04 5.65 3.35 1.83
SD 205.51 7.87 0.96 1.43 1.19 0.43
SE 91.91 3.52 0.43 0.64 0.53 0.19
M 1622.00 36.76 1.67 6.06 3.27 1.73
LN n 4 4 4 4 4 4
x 1887.75 25.12 1.76 5.21 5.16 2.77
SD 126.71 1.13 0.61 1.06 1.03 1.01
SE 63.36 0.56 0.31 0.53 0.52 0.51
M 1897.00 25.20 1.76 5.18 5.24 2.59
LN/LA n 7 7 7 7 7 7 v
x 1734.57 34.32 1.76 6.18 4.32 2.10
SD 254.05 9.03 0.48 2.07 2.21 1.18
SE 96.02 3.41 0.18 0.78 0.84 0.45
M 1791.00 32.42 1.66 5.21 4.03 1.95
Groups: LN/LA – L-NAME- and L-arginine, LN – L-NAME, LA
– L-arginine, C – control; Body weight – BW; Liver index – LI,
Spleen index – SI, Heart index – HI, Thymus index – TI, Bursa
of Fabricius index – BFI; gram – gm; n – number of animals, x –
mean values
cribed12,23,59,60, but it has been previously considered as a
normal finding in healthy birds23. In the fourth week of
the study, atrial collapse and parabronchial dilatation
was observed in the lungs of the birds treated with
L-NAME. The same changes were confirmed in the lungs
of ascitic broiler chickens12,23. In the L-NAME-treated
group of chickens and in the L-arginine-group (Figure 5),
a fibrin-like protein matter was visible perivascularly in
the fifth week of trial. In the state of PHS, pulmonary
capillaries can undergo the so-called »stress-caused fail-
ure« due to increased pressure. Then the blood can flow
out through pulmonary airways, disturbing gases ex-
change61. Considering the finding of a high degree pul-
monary edema, in the same study week (L-NAME group),
this finding of perivascular fibrinoid matter could be as-
sociated with the increased permeability of pulmonary
blood vessel walls. Moreover, during the oxidative lungs
damage the reduced pressure in the airways, edema and
the finding of protein-like secret in the air spaces after
the administration of L-NAME were confirmed62. The
cause of the microscopic appearance of fibrinoid matter
in lungs of L-arginine-treated chickens was not deter-
mined. The possibility that the histopathological change
of fibrinoid matter could be a plasma would support the
accumulating evidence for the involvement of NO in
plasma extravasation during the various forms of infla-
mmation63. However, the pathomorphological changes
typical for the inflammation were not confirmed in L-ar-
ginine-treated chickens sacrificed at the end of the pres-
ent experiment.
In the last weeks of the present trial, the thickening
of the medial layer and migration of smooth muscle cells
into the subintima of the pulmonary arterioles was ob-
served in the L-NAME-group (Figure 7). Similar patho-
logical changes were described in broilers with chronic
PH64,65. However, these findings could not be expected in
L-arginine group because the proliferation of smooth
muscle cells in pulmonary arteriole was inhibited by
L-arginine66. For the histopathological evaluation it is
important to know that some broiler chicken hybrids
have an innately thickened arterial wall layer67, whereas
the others attributed this change exclusively to the chi-
ckens with PHS55, as the consequence of elevated pulmo-
nary arteriolar pressure that results in hypertrophy of
the smooth muscle layer in the small arterioles of the
lungs – the resistance vessels46.
In the bursa of Fabricius, thymus, and in the spleen of
the chickens in the L-NAME group, a low-degree deple-
tion of lymphocyte-type cells was present. The same find-
ings were reported in all the analysed organs of ascitic
chickens explaining the findings as immunosuppressive
action of a chronic disease55.
The significance of cardiac index in ascitic chickens is
the key to haemodynamic disorders – to hypoxemia and
definitive cardiovascular system failure in fast growing
broiler chickens. In this production category of the poul-
try, the value of cardiac index is inheritedly low17. In
present investigation it was not able to find any regular-
ity concerned the possible elevation of heart index value
in L-NAME group toward the end of the experiment, i.e.,
in a period in which also the other parameters (gross le-
sions and histopathology) had confirmed the presence of
pre-ascitic (hypoxic) and/or ascitic state (Table 2).
It has been interesting that the liver index in L-
-NAME/L-arginine-group was significantly lower than
the index values in both L-NAME-group and in L-ar-
ginine-group of chickens in the first trial week (Table 1),
and the same relation was recorded during the same
week in the heart index values between the same groups
of chickens (Table 2). Nevertheless, the relative liver
weight followed by the heterophil/lymphocyte ratio and
the percentage weights of immunocompetent organs rep-
resent the excellent indicators of the stress condition68.
According to these authors the increasing of the liver
weight is one of the signs of the stress.
Relative spleen weight is also a general indicator of
stress68,69. Although long-term responses to stressors ge-
nerally result in decreased lymphoid mass70, the spleen
index values shown from the first to the fifth weeks in
the present experiment did not confirm this data (Table 3).
In conclusion, the pathomorphology results of investi-
gation of chronic toxicity dynamics of L-NAME con-
firmed its toxic (vasoconstrictive and hypoxic) effect:
pre-ascitic condition and/or ascites – PHS developed in
the chickens treated with L-NAME over five weeks. Mi-
croscopic changes in the chickens in the L-NAME group
were consistent with its systemic action (edema, dysoria)
and with topical irreversible damage to individual tissues
(tissue tropism /disruption of myofibriole, hepatal ce-
llulolysis/), mainly after a longer period of the compound
administration. L-arginine displayed prominent conges-
tions and haemorrhages in the heart, lung and liver tissues.
These effects proved to be directly dependent on the
L-arginine and on the L-NAME concentrations, and on
the duration of the treatment with these compounds.
In the groups simultaneously administered L-NAME
and L-arginine, histopathology analysis established a
lower degree to a complete absence of pathological chan-
ges otherwise established in the tissues of chickens re-
ceiving L-NAME alone. This corroborated the effect of
L-arginine, i.e., of NO, confirmed in several literature re-
ports so far, that it prevents and alleviats, or possibly
treats vasoconstrictive (ischemic) cardiovascular disor-
ders that in the majority of cases progress from localized
to systemic (pulmonary hypertension syndrome and chro-
nic right atrial failure, ascites).
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U^INAK KRONI^NE TOKSI^NOSTI L-NAME I L-ARGININA NA POJAVU ASCITESA – SINDROMA
PLU]NE HIPERTENZIJE U TOVNIH PILI]A
S A @ E T A K
U~inak kroni~ne toksi~nosti L-arginina i N-w-nitro-L-arginin-metil-estera – L-NAME na pojavu ascitesa – sindroma
plu}ne hipertenzije (SPH) istra`ivan je u 140 tovnih pili}a mu{koga spola (ROSS) u razdoblju od prvog dana do petog
tjedna `ivota. Pili}ima podijeljenim u ~etiri skupine injicirano je intraperitonealno (ip) svaki drugi dan 0,5 mL/kg tj. m.
fiziolo{ke otopine (kontrolna skupina, K); 10 mg/kg tj. m. L-NAME (LN-skupina); 100 mg/kg tj. m. (L-arginin; LA-
-skupina) i 10 mg/kg tj. m. L-NAME i 100 mg/kg tj. m. L-arginina (LN/LA-skupina). Na kraju svakoga tjedna eutanazi-
rano je po sedam pili}a iz svake skupine. Uzorci srca, jetre, plu}a, krvnih `ila i limfoidnih organa podvrgnuti su patolo-
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{kohistolo{koj pretrazi. Odre|en je tako|er i pokazatelj odnosa mase jetre, slezene, srca i timusa u usporedbi s tjelesnom
masom (indeks mase organa). Na kraju pokusa u pet uginulih pili}a iz skupine tretirane s L-NAME (LN-skupina)
utvr|en je ascites – SPH. U istoj je skupini tijekom pokusa edem utvr|en kao prevladavaju}a patolo{kohistolo{ka pro-
mjena u srcu i plu}ima pili}a. U skupini tretiranoj L-argininom najizra`enije su bile patolo{kohistolo{ke promjene
punokrvnosti i krvarenja poglavito tijekom posljednja dva tjedna pokusa. Dok su `ari{na disrupcija miovlakana srca i
disrupcija hepatocita prevladavale u pili}a tretiranih s L-NAME (5. tjed. pokusa), u skupini tretiranoj istodobno L-argi-
ninom i s L-NAME utvr|ena je degeneracija sr~ana mi{i}a manjeg stupnja jakosti. Razudbom utvr|enim preasciti~nim
stanjem ili ascitesom-SPH u uginulih tovnih pili}a skupine LN krajem petoga tjedna potvr|ena je uloga L-NAME u
nastanku ove metaboli~ke bolesti tovnih pili}a, dok je nalaz u pili}a tretiranih L-argininom ukazao na protektivni
u~inak glede nastanka ascitesa – SPH u tovnih pili}a.
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